Сравнение
Cagrilintide vs. Efinopegdutide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
1415456-99-3
2055640-93-0
Молекулярная масса
4253.7 g/mol
нет данных
Период полувыведения
168 h
115 h
Последовательность
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYmodifiziertes, von Oxyntomodulin abgeleitetes Peptid, konjugiert an ein humanes IgG4-Fragment (Verlängerung der Plasma-Halbwertszeit)Механизм действия
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Efinopegdutide
Efinopegdutide is an oxyntomodulin-derived peptide acting as a dual agonist at the GLP-1 and glucagon receptors with a relative potency of approximately 2:1 (GLP-1 to glucagon). The GLP-1 component mediates glucose-dependent insulin secretion and modulation of satiety; the glucagon component increases energy expenditure and hepatic fat oxidation, which is proposed to contribute to the observed reduction in liver fat. Conjugation to an IgG4 fragment prolongs the half-life and enables weekly administration.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
4
3
из них на людях
3
3
Зафиксированные эффекты
3
4
Открытые противоречия
1
1
Задокументированные нежелательные явления
1
1
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Cagrilintide and Efinopegdutide?
- Cagrilintide is classified as "Метаболизм", while Efinopegdutide is classified as "Метаболизм". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Efinopegdutide: Efinopegdutide (MK-6024, formerly JNJ-64565111 / HM12525A) is a once-weekly dual agonist at the GLP-1 and glucagon receptors, developed by Hanmi and Merck. It has been studied for obesity and notably for metabolic liver disease (MASH/NAFLD); a phase-2 trial showed greater liver-fat reduction than semaglutide. Investigational, not approved. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Cagrilintide or Efinopegdutide?
- The highest available evidence level is "РКИ на людях" for Cagrilintide and "РКИ на людях" for Efinopegdutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Cagrilintide and Efinopegdutide in Germany and the United States?
- Германия: Cagrilintide — Не одобрено, Efinopegdutide — Не одобрено. США: Cagrilintide — Не одобрено, Efinopegdutide — Не одобрено. These are factual summaries with source and review date on the individual pages.